Gilteritinib
CAS 1254053-43-4 2 FDA-DMF suppliersSmall Molecule
Overview
Gilteritinib is a small molecule inhibitor targeting the FMS-like tyrosine kinase 3 (FLT3) receptor, used primarily in the treatment of acute myeloid leukemia (AML). It is effective in AML patients with a mutation in the FLT3 gene.
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Gilteritinib expires 30 Jun 2036. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyHematologic Malignancies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.